We’re proud to share that VeriSIM Life has been named a finalist for the 2026 𝐂𝐏𝐇𝐈 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐂𝐚𝐭𝐚𝐥𝐲𝐬𝐭 𝐀𝐰𝐚𝐫𝐝. AI can generate more molecules and more predictions than ever before. But the hardest question in drug development remains: 𝐖𝐡𝐢𝐜𝐡 𝐝𝐫𝐮𝐠 𝐰𝐢𝐥𝐥 𝐚𝐜𝐭𝐮𝐚𝐥𝐥𝐲 𝐰𝐨𝐫𝐤 𝐢𝐧 𝐡𝐮𝐦𝐚𝐧𝐬? That is what we built BIOiSIM® to answer. By combining mechanistic biology, biosimulation and explainable AI, BIOiSIM helps teams understand not only what is predicted, but 𝐰𝐡𝐲, 𝐰𝐡𝐞𝐭𝐡𝐞𝐫 𝐭𝐡𝐞 𝐛𝐢𝐨𝐥𝐨𝐠𝐲 𝐰𝐢𝐥𝐥 𝐭𝐫𝐚𝐧𝐬𝐥𝐚𝐭𝐞, 𝐚𝐧𝐝 𝐰𝐡𝐢𝐜𝐡 𝐝𝐫𝐮𝐠 𝐢𝐬 𝐰𝐨𝐫𝐭𝐡 𝐚𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠. Because generating candidates is getting easier. 𝐊𝐧𝐨𝐰𝐢𝐧𝐠 𝐰𝐡𝐢𝐜𝐡 𝐨𝐧𝐞 𝐜𝐚𝐧 𝐛𝐞𝐜𝐨𝐦𝐞 𝐚 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐢𝐬 𝐭𝐡𝐞 𝐫𝐞𝐚𝐥 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞. Proud to see this work recognized by CPHI. #CPHI2026 #DrugDevelopment #TranslationalScience #BIOiSIM

A meaningful milestone for a program that started at VeriSIM Life. PulmoSIM Therapeutics has received a U.S. Notice of Allowance for a foundational patent covering PT001, a first-in-class inhaled therapy for pulmonary hypertension and other serious pulmonary diseases. PT001 was designed using our BIOiSIM® platform, bringing together mechanistic biology and AI to make better decisions about efficacy, safety, and human translation. Seeing a program move from computational design to promising preclinical results, and now toward the clinic, is exactly why we built BIOiSIM. Congratulations to the PulmoSIM team. Excited for what comes next! Read the press release: na2.hubs.ly/H078btl0 #PulmonaryHypertension #DrugDevelopment #AI #Biotech

🚀 Advancing the future of drug development, one breakthrough at a time! We're thrilled to share that VeriSIM Life has been named a Phase 1 winner of the NIH Complement-ARIE NAMs Reduction to Practice Challenge for our project, "Combinatorial NAM for Endometriosis Drug Efficacy."  The Complement-ARIE Challenge was created to accelerate the real-world adoption of New Approach Methodologies (NAMs): innovative technologies that improve the prediction of human responses while reducing dependence on animal studies. By encouraging the integration of AI, computational biology, and other cutting-edge scientific methods, the challenge is helping reshape how new medicines are discovered and developed. Our project focuses on one of the most challenging areas in women's health, endometriosis. By combining VeriSIM Life's AI-powered translational biosimulation platform with complementary NAM technologies, we're working to identify more effective therapies with greater confidence before they reach the clinic. This recognition reflects our commitment to building a future where drug development is faster, more predictive, and more human-relevant. Thank you to the NIH for supporting innovation in this critical field, and congratulations to our outstanding research team. We're excited for what's ahead as we move into Phase 2. #DrugDiscovery #NIH #Endometriosis #AI #NAMs #WomenInHealth #Biotechnology #MachineLearning #TranslationalScience #VeriSIMLife

🏆 Big news from VeriSIM Life!! We're proud to announce that our submission, "Combinatorial NAM for Endometriosis Drug Efficacy," has been selected as a Phase 1 winner in the NIH Complement-ARIE NAMs Reduction to Practice Challenge. This challenge recognizes innovative approaches that accelerate the adoption of New Approach Methodologies (NAMs), scientifically advanced technologies designed to improve how therapies are evaluated while reducing reliance on traditional animal testing. Our winning approach combines AI-powered biosimulation with complementary NAM technologies to better predict drug efficacy for endometriosis, a disease that affects millions of women worldwide yet remains underserved by current treatment options and preclinical models. At VeriSIM Life, we believe the future of drug development depends on integrating human-relevant data, mechanistic biology, and artificial intelligence to make earlier, smarter decisions. This recognition from the NIH reinforces the growing importance of computational and translational approaches that can help identify promising therapies faster, reduce costly failures, and bring better medicines to patients sooner. Congratulations to our incredible team on this achievement! #NIH #DrugDiscovery #AI #Endometriosis #NAMs #Biosimulation #ArtificialIntelligence #Biotech #PrecisionMedicine #VeriSIMLife

🔬 What does it take for AI to earn trust in drug development? Not just faster predictions. Better science. We're proud to announce that VeriSIM Life has formalized a research collaboration with the FDA's National Center for Toxicological Research (FDA/NCTR), reinforcing our shared commitment to advancing mechanistically grounded, scientifically explainable AI for drug development. As the industry moves beyond AI hype and toward real-world implementation, the focus is shifting to a critical question: Can AI produce insights that are transparent, biologically defensible, and fit for regulatory decision-making? Our BIOiSIM® platform was built to do exactly that, combining mechanistic modeling with AI to improve translational predictability, identify safety risks earlier, and support more informed development decisions across the drug lifecycle. This collaboration builds on our ongoing scientific engagement with FDA/NCTR researchers and published work demonstrating BIOiSIM's ability to predict drug-induced liver injury through integrated computational modeling. The future of drug development won't be powered by black-box predictions. It will be driven by explainable, human-relevant science.  Read the full announcement: na2.hubs.ly/H06lS560  #DrugDevelopment #ArtificialIntelligence #Biotech #Pharma #RegulatoryScience #ComputationalBiology #MachineLearning #NAMs #PrecisionMedicine #LifeSciences #FDA

AI is rapidly reshaping biotech, but the real opportunity isn’t just discovering drugs faster. It’s making smarter development decisions before billions of dollars and years of time are on the line 💡 That’s exactly why VeriSIM Life is heading to BIO International Convention 2026 🚀 BIO is where the industry’s biggest players come together to discuss what’s next in pharma, biotech, investment, and healthcare innovation. We’re excited to be part of the conversation around how AI can improve translational success, reduce development risk, and help bring better therapies to patients faster 🧠 If you’re attending BIO 2026, let’s connect. To schedule time with our team, reach out to VP of Corporate Development Gordon Murtaugh at [email protected]. #BIO2026 #BIOInternational #AIinDrugDevelopment #Biotech #Pharma #HealthcareInnovation #DrugDiscovery

BIO International Convention 2026 brings together the people making billion-dollar decisions in biotech and pharma, and VeriSIM Life is excited to be part of it 🌍 The future of drug development won’t be defined by speed alone. It will be defined by who can make better decisions earlier: which therapies to advance, which risks to eliminate, and how to improve the odds of clinical success. That’s the shift AI is driving across the industry today 🧠 We’re looking forward to meeting with partners, investors, and innovators who are thinking seriously about the next generation of translational science and AI-enabled development. Attending BIO 2026? Let’s connect. To set up time with our team, contact Gordon Murtaugh at [email protected]. #BIO2026 #Biotech #Pharma #AIinHealthcare #DrugDiscovery #HealthcareInnovation 🚀

💡 What if every investigational drug had a "credit score" for clinical success? That's the vision discussed by Dr. Jo Varshney, Founder and CEO of VeriSIM Life, in a recent Bio-IT World feature by Deb Borfitz. The article explores how AI-powered biosimulation and mechanistic modeling can help biopharma companies assess translational risk earlier, before costly clinical failures occur. Rather than relying solely on historical data or trial-and-error approaches, predictive, human-relevant models can provide a more dynamic view of how therapies are likely to perform in humans. As pressure grows to improve R&D productivity, reduce animal usage, and make smarter capital allocation decisions, the industry's focus is shifting from generating more data to generating more actionable insight. The future of drug development may belong to organizations that can identify risk sooner, prioritize programs more effectively, and make higher-confidence decisions across the pipeline. 🚀 Thank you to Deb Borfitz and the Bio-IT World team for highlighting this important conversation shaping the future of translational science. What do you think will have the biggest impact on improving clinical success rates over the next decade: AI-powered biosimulation, better biomarkers, improved trial design, or something else? Article: na2.hubs.ly/H067Rql0 #DrugDevelopment #AI #Biotech #Pharma #Biosimulation #PrecisionMedicine #ClinicalTrials #DigitalHealth #LifeSciences #Innovation #BioITWorld

The economics of drug development are changing fast, and AI is becoming impossible to ignore 📈 At BIO International Convention 2026, VeriSIM Life will be joining leaders across biotech and pharma to discuss how the industry can reduce failure rates, accelerate development, and make earlier decisions with greater confidence. As pressure grows to deliver therapies faster and more efficiently, companies are rethinking how they evaluate risk across the pipeline. AI is no longer just a discovery tool; it’s becoming a strategic advantage across translational science and clinical prediction. 🧬 We’re excited to be part of the conversations shaping what comes next. If you’ll be at BIO, let’s meet. Reach out to Gordon Murtaugh, VP of Corporate Development, at [email protected] to connect. #BIO2026 #AIinBiotech #DrugDevelopment #BiotechInnovation #PharmaLeadership 🚀

What does it really take to build a company that creates lasting impact? This recent article highlights the resilience, vision, and leadership behind the women entrepreneurs recognized on the Inc. Female Founders 500 list. It's a powerful reminder that transformative companies are built by leaders willing to challenge convention, navigate uncertainty, and keep moving forward. We're proud that VeriSIM Life CEO Dr. Jo Varshney was recognized among this remarkable group of founders. As AI continues to reshape healthcare and drug development, we're grateful to be part of a community of innovators working to solve some of the world's most complex challenges. Thank you to Inc. for spotlighting the leaders and companies driving meaningful change across industries. Congratulations to all of the founders recognized this year; we're honored to be in such exceptional company. 🚀 na2.hubs.ly/H061xQG0 #FemaleFounders500 #Leadership #Entrepreneurship #Biotech #AI #HealthcareInnovation #DrugDevelopment #WomenInBusiness #VeriSIMLife

Drug development is entering a new era, and the conversations shaping it are happening at BIO International Convention 2026 🚀 VeriSIM Life will be joining biotech innovators, pharma executives, investors, and policymakers to discuss the future of AI-driven R&D and translational science. The industry is under pressure to move faster while making smarter decisions earlier. That’s where AI is beginning to change the equation: reducing development risk, improving prediction, and helping companies focus resources on therapies with the highest probability of success 🧠 If you’re attending BIO 2026, let’s connect. We’d love to discuss how AI can help accelerate timelines, strengthen pipeline strategy, and improve clinical translation. To schedule time with our leadership team, reach out to VP of Corporate Development Gordon Murtaugh at [email protected]. #BIO2026 #BIOInternational #Biotech #Pharma #AI #DrugDevelopment #PrecisionMedicine

Grateful to Roivant Social Ventures for convening the 3rd Annual Convergence Forum Fellowships Program, an exceptional gathering of leaders advancing healthcare innovation and equity across biotech, pharma, and beyond. It was an honor for Dr. Jo Varshney to join this year’s cohort of Convergence Forum Fellows alongside fellow CEOs working at the intersection of therapeutics, diagnostics, and enabling technologies to improve outcomes for underserved and vulnerable patient populations. The Convergence Forum continues to be a rare space where science, capital, and policy come together for candid, high-impact dialogue on what it will take to meaningfully transform healthcare systems and accelerate translational progress. We’re energized by the conversations and excited to continue building toward more predictive, inclusive, and patient-centered drug development. #HealthcareInnovation #HealthEquity #Biotech #DrugDevelopment #ConvergenceForum 🚀

#LondonTechWeek 2026 is where the future of AI gets defined, and Dr. Jo Varshney is stepping into that conversation 🚀 Taking the stage at Olympia London, she’ll join a global lineup of founders, investors, and policymakers to explore how AI is transforming industries at scale. Her panel, “Permission to Innovate: What It Really Means to Build a Company With AI at the Core,” gets at a critical shift: moving from experimentation with AI to truly operationalizing it. Alongside Dr. Varshney will be Tara Lajumoke at Myora Health and Varun Bhanot at MAGIC AI as panelists, with the session moderated by Paige Hookway at Startups Magazine. With past speakers and attendees including Jensen Huang of NVIDIA and the UK Prime Minister, London Tech Week has become a global stage where the world’s technology agenda is actively shaped, not just discussed. In drug development, that shift carries enormous weight. It’s not just about building smarter tools; it’s about making better decisions, earlier. At VeriSIM Life, that’s exactly the focus. As the industry pushes into uncharted territory, the winners won’t be those generating the most data, but those turning it into confident, actionable insight 🧠 #AIinDrugDevelopment #LondonTechWeek2026 #LTW2026

BIO International Convention 2026 is where biotech’s biggest conversations happen, and VeriSIM Life will be in the room 🚀 This is where pharma leaders, emerging biotechs, investors, and policymakers come together to shape what’s next in drug development. We’re there to talk about what’s changing fast: how AI is shifting decisions earlier, reducing risk, and accelerating the path from idea to patient 🧠 If you’re attending, let’s connect. Whether you’re looking to de-risk your pipeline, speed up timelines, or rethink your R&D strategy, we’d love to meet. To set up time, reach out to VP of Corporate Development Gordon Murtaugh at [email protected]. #BIO2026 #BIOInternational #AIinDrugDevelopment

Proud to share that Dr. Jo Varshney has been invited to speak at AstraZeneca’s prestigious Global 3Rs Week, a global forum held by C‑SAW (Council for Science and Animal Welfare) at AstraZeneca, that brings together scientific leaders focused on advancing more ethical, human-relevant approaches to drug development. Her talk, “Rethinking Drug Development with Translational AI and Ethical Science,” sits at the heart of a critical industry conversation: how do we accelerate breakthrough therapies while reducing reliance on animal testing and improving translational predictability for patients? The principles of the 3Rs — Replacement, Reduction, and Refinement — are no longer peripheral to innovation. They are becoming essential to the future of modern drug development. At VeriSIM Life, this mission has always been core to our work: using explainable AI and virtual translational models to help researchers make earlier, more human-relevant decisions about safety and efficacy. This ultimately reduces unnecessary animal studies, lowers costly late-stage failures, and helps better therapies reach patients faster. We are honored to contribute to a global conversation shaping the future of ethical science and translational medicine. #3Rs #DrugDevelopment #AI #Biotech #TranslationalScience #EthicalScience #PharmaInnovation

💡 The FDA’s shift toward a single pivotal trial is changing the game in drug development, moving risk upstream and making early decisions more critical than ever. As highlighted in First Word Pharma, our CEO Dr. Jo Varshney emphasizes that designing a robust pivotal trial requires deep understanding of patient variability, endpoints, and real-world biological complexity. “All of those things have to be considered early on to design a robust pivotal trial,” she notes. At VeriSIM Life, our AI-driven BIOiSIM platform empowers teams to de-risk early, refine strategy, and make human-relevant decisions with confidence... because in today’s landscape, getting it right the first time is essential. ⚡ #AIinDrugDevelopment #TranslationalScience Article ➡️ na2.hubs.ly/H05t4-T0

We’re excited to share that Dr. Jo Varshney has been selected as an exclusive fellow of the Convergence Forum, an invitation-only convening of CEOs shaping the future of healthcare. This fellowship, led by Roivant Social Ventures, recognizes leaders advancing healthcare equity through therapeutics and technology designed to better serve underserved and underrepresented patient populations. This recognition reflects a structural shift in how the industry approaches drug development. For decades, translational gaps and limited representation in early research have constrained both clinical success and equitable access. The result is not only inefficiency, but a system that too often fails to reflect real human biology at scale. At VeriSIM Life, this problem is addressed at its source. The BIOiSIM® platform enables human-relevant, mechanistically grounded predictions of safety, efficacy, and dosing before clinical trials begin. By integrating explainable AI with translational biology, it provides a decision framework that improves capital allocation, reduces late-stage failure risk, and supports development strategies that account for diverse patient populations from the outset. The Convergence Forum convenes leaders across pharma, diagnostics, and medtech to advance a more predictive and more equitable healthcare system. This fellowship recognizes those building the underlying infrastructure to make that shift real. Grateful to Roivant Social Ventures for the invitation and for creating a forum where scientific rigor, translational strategy, and equity are addressed as one system-level challenge! #HealthcareEquity #TranslationalScience #AIinBiology #DrugDevelopment #BiotechLeadership

Our Founder and CEO, Dr. Jo Varshney, has been named to Inc.’s 2026 Female Founders 500. We couldn’t be prouder. Dr. Varshney founded VeriSIM Life on a conviction that the gap between animal experiments and human biology should no longer determine whether a medicine succeeds or fails. That conviction led her to build BIOiSIM®, our translational AI platform that helps pharma and biotech teams predict drug safety, efficacy, and dosing before a single patient enters a clinical trial. Inc. specifically recognized Dr. Varshney for validating the predictive accuracy of our AI-powered drug development platform and initiating health-system partnerships that are redefining how medicines reach patients. Under her leadership, VeriSIM Life has raised over $25M, built a robust therapeutic pipeline, and advanced our lead drug candidate toward its first human clinical studies. None of it happens without the team behind the science and technology, and none of it matters unless it gets better therapies to patients faster. That’s the mission. That’s what drives us. Congratulations, Dr. Varshney. #FemaleFounders500 #AIinDrugDevelopment #BIOiSIM #VeriSIMLife #WomenInAI #DrugDevelopment #BioTech #HealthTech

At VeriSIM Life, our mission has always been to close the translational gap between preclinical research and successful clinical outcomes. As highlighted in a recent feature in the AJMC - The American Journal of Managed Care, integrating AI-driven data from multiple species, from rodents to humans, is transforming how preclinical studies are designed and interpreted. By harnessing advanced simulations that blend mechanistic biology with AI, we’re helping researchers choose better models, reduce unnecessary animal testing, derisk development, and get therapies to patients faster and more cost-effectively with our BIOiSIM platform. But this isn’t just about efficiency; it’s about improving predictive accuracy and reshaping expectations around how early-stage research informs human trials. 👉 Discussion question: If AI models rely on existing animal and human datasets to predict translational outcomes, how do we ensure that the insights AI generates don’t just reinforce inherent biases in those datasets and truly improve our ability to predict human responses? Article: ajmc.com/view/how-ai-driven-…

At the 3DCC International Conference on Advances in 3D Cell Culture in Goa, Dr. Varshney was proud to join a group of AI leaders who are moving beyond high-level conversations and into real implementation, especially in biologics. The dialogue was practical, technically grounded, and future-focused. One takeaway stood out: India is not simply adopting AI in life sciences. It is playing an active role in defining how the field evolves. 🌏🧬 At VeriSIM Life, we discussed how our BIOiSIM platform combines AI with mechanistic biology to improve translational prediction and reduce unnecessary reliance on animal testing, particularly for complex biologics. The conversation went into the realities of adoption, including how organizations build confidence in model outputs, how regulatory expectations are shaping development strategies, and why data rigor and biological relevance matter more than headline speed. Discussions like this reflect a broader shift across the industry. The focus is shifting from proof-of-concept AI to systems that support real decisions, align with regulatory frameworks, and deliver measurable impact on costs, timelines, and patient outcomes. Thank you to the 3DCC organizers for a thoughtful and well executed event! #AIinDrugDevelopment #Biologics